Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
236 studies found for:    c-kit
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
Conditions: cKIT-positive Solid Tumors;   AML
Intervention: Drug: LOP628
2 Completed cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Condition: Melanoma
Intervention: Other: sequencing
3 Recruiting Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML
Condition: Acute Myeloid Leukemia
Intervention: Drug: midostaurin (PKC412)
4 Active, not recruiting A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
5 Completed A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
Condition: Leukemia
Intervention: Drug: Imatinib (Gleevec)
6 Completed
Has Results
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Condition: Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: Imatinib mesylate
7 Unknown  A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Condition: Metastatic Melanoma
Interventions: Drug: masitinib;   Drug: Dacarbazine
8 Withdrawn Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
Condition: Metastatic Solid Tumors.
Intervention: Drug: Glivec
9 Unknown  Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: NOVE-HiDAC;   Drug: Nilotinib
10 Unknown  A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
11 Active, not recruiting Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Condition: Leukemia
Interventions: Drug: imatinib mesylate;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: biopsy
12 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
13 Completed Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Conditions: Sarcoma;   Gastrointestinal Stromal Tumors
Intervention: Drug: Imatinib mesylate (Glivec)
14 Active, not recruiting Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Condition: Asthma
Interventions: Drug: Imatinib mesylate;   Drug: Placebo
15 Completed Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: NILOTINIB;   Drug: EVEROLIMUS
16 Completed Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors
Conditions: Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach;   Investigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients
17 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
18 Completed Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Imatinib Mesylate;   Drug: Docetaxel
19 Completed High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
Condition: AML
Intervention: Drug: Imatinib
20 Completed Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
Condition: Small Cell Lung Cancer
Intervention: Drug: Gleevec

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years